Beyond Insulin Sensitivity: New Trial Reveals Metformin’s Surprising Role in Type 1 Diabetes

GLASGOW — A cornerstone of type 2 diabetes management for decades, the inexpensive drug metformin may offer a secondary benefit for those living with type 1 diabetes (T1D). According to the results of the recent INTIMET randomized clinical trial, metformin significantly reduced the daily insulin requirements for adults with T1D over a 26-week period. However, the study yielded a surprising twist: the reduction in insulin use was not caused by an improvement in insulin resistance, as researchers had long hypothesized, suggesting that the “gold standard” drug may work through pathways that medical science is only beginning to map.

A Shift in the Scientific Narrative

For years, clinicians have explored “off-label” uses for metformin in type 1 diabetes, hoping it might help patients who struggle with “double diabetes”—a condition where individuals with T1D also develop features of insulin resistance typically seen in type 2.

The INTIMET trial, a double-blind, placebo-controlled study, sought to provide definitive evidence. While the primary goal was to measure changes in insulin sensitivity, the data revealed that metformin failed to significantly improve how the body’s cells respond to insulin. Yet, despite this, participants on metformin required lower total daily doses of insulin compared to those in the placebo group.

“The fact that insulin doses dropped without a measurable change in insulin resistance is a fascinating clinical paradox,” says Dr. Elena Rossi, an endocrinologist not involved in the study. “It suggests that metformin’s magic in type 1 might be happening in the gut or through metabolic pathways we haven’t prioritized in T1D research until now.”

The Weight of the Evidence: From REMOVAL to INTIMET

The INTIMET findings do not exist in a vacuum. They build upon the landmark REMOVAL trial, the largest study of its kind, which followed over 400 adults with T1D for three years.

While REMOVAL also found that metformin did not provide a sustained improvement in blood sugar levels (HbA1c), it did highlight three consistent benefits:

1. Weight Management: Participants lost an average of 1.17 kg (roughly 2.6 lbs).

2. Cardiovascular Health: A reduction in LDL (“bad”) cholesterol by 0.13 mmol/L.

3. Insulin Sparing: A persistent, albeit small, reduction in the amount of insulin needed daily.

In the world of type 1 diabetes, where insulin is the only life-sustaining treatment, reducing the dose is more than just a numbers game. High doses of insulin are frequently associated with weight gain and an increased risk of hypoglycemia (dangerously low blood sugar). A “sparing effect” could potentially improve long-term cardiovascular outcomes and reduce the daily burden of disease management.

Understanding the Difference: Type 1 vs. Type 2

To understand why these findings are nuanced, it is essential to distinguish between the two primary forms of diabetes:

Expert Caution: Not a “One-Size-Fits-All” Solution

Despite the promising news regarding insulin doses, the medical community remains cautious. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) emphasized in a 2021 consensus report that insulin remains the non-negotiable foundation of T1D care.

Independent experts point out that metformin is not without side effects. Gastrointestinal distress—including nausea and diarrhea—is common, and long-term use can lead to vitamin B12 deficiency.

“We have to be careful not to over-promise,” cautions Dr. Sarah Jenkins, a clinical researcher in metabolic health. “Metformin is a tool, not a cure. For a patient who is already at a healthy weight and has stable glucose levels, the side effects might outweigh the minor benefit of a slightly lower insulin dose.”

Public Health and Daily Decisions: What This Means for You

For the roughly 9 million people worldwide living with type 1 diabetes, the INTIMET trial offers a glimmer of hope for more flexible treatment “toolkits.”

Practical Takeaways for Patients:

• Don’t Self-Prescribe: Never start metformin without a prescription. It can interact with other conditions, particularly kidney disease.

• Targeted Use: Metformin may be most beneficial for T1D patients who are overweight or have high cholesterol.

• Focus on the Foundation: The primary goal of T1D management remains stable blood sugar through precise insulin dosing and technology (like CGMs and pumps).

The “Cheap Drug” Advantage

From a public health perspective, metformin’s greatest strength is its cost. As a generic medication, it is widely available and incredibly inexpensive. If further, larger-scale trials confirm that metformin can safely reduce insulin needs and protect the heart, it could provide a low-cost way to improve the quality of life for T1D patients globally, especially in low-resource settings.

Limitations and the Road Ahead

The INTIMET trial was relatively small and lasted only six months. While this is sufficient to observe metabolic changes, it cannot prove that metformin prevents long-term complications like heart attacks or kidney failure in Type 1 patients. Furthermore, because the “insulin-sparing” effect was a secondary outcome, researchers view it as a “hypothesis-generating” result rather than a final verdict.

As science moves forward, the focus is shifting toward the gut microbiome and various hormonal signals that metformin influences. The next decade of research may finally determine if this old drug can truly learn new tricks for Type 1 diabetes.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.earth.com/news/new-study-shows-metformin-helps-people-with-type-1-diabetes-in-surprising-ways/